The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

Overview

Patients with Myeloma or CLL with severe secondary hypogammaglobinemia and recurrent infections will be included in this study; for whom an IgSC treatment was prescribed. The IgSC prescription will be the decision of the treating physician. Patient care and follow up will be performed according to the current clinical practice and the recommendations of HAS.

Full Title of Study: “Effect of Subcutaneous Immunoglobulin (IgSC) Gammanorm® on the Distribution of IgG Subclasses and on the Humoral Immunity of Patients With Secondary Immunodeficiency.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 22, 2019

Interventions

  • Drug: Gammanorm
    • Gammanorm given per standard of care
  • Drug: Other Subcutaneous Immunoglobulins
    • Other Subcutaneous Immunoglobulins given per standard of care

Arms, Groups and Cohorts

  • Gammanorm
    • Patients on Gammanorm per standard of care
  • Other Subcutaneous Immunoglobulin
    • Patients on subcutaneous immunoglobulin treatments other than Gammanorm

Clinical Trial Outcome Measures

Primary Measures

  • Distribution of difference subclasses of IgGs with respect to subcutaneous immunoglobulin treatment
    • Time Frame: 12 months
    • Distribution of difference subclasses of IgGs with respect to subcutaneous immunoglobulin treatment collected as biological data including immunoglobulins (quantitative dosage and electrophoresis), lymphocytes, CD14 monocytes, polynuclear neutrophils, polynuclear basophils and dendritic cells

Secondary Measures

  • Change in immune system
    • Time Frame: 12 months
    • To analyze the change in the immune system (CD14 monocytes, polynuclear neutrophils, polynuclear basophils and dendritic cells)
  • IgG levels
    • Time Frame: 12 months
    • To analyze the IgG levels with respect to the IgSC treatment
  • Lymphocytic Repertoire analyzing the evolution of the lymphocytic repertoire (CD3, CD4, CD8, CD19, CD56, and CD27).
    • Time Frame: 12 months
    • To analyze the evolution of the lymphocytic repertoire (CD3, CD4, CD8, CD19, CD56, and CD27).
  • IgSC treatment
    • Time Frame: 12 months
    • To characterize the IgSC treatment duration and the patient management (observance, duration and reason of termination)
  • Bacterial Infections
    • Time Frame: 12 months
    • To evaluate the severe and non-severe bacterial infection rates
  • Antibiotic Consumption
    • Time Frame: 12 months
    • To evaluate the antibiotics consumption during the study
  • Hospitalizations due to infections
    • Time Frame: 12 months
    • Evaluate the hospitalization rates due to infections
  • Safety of IgSCs to characterize the IgSCs safety, including the adverse events that are not considered to be related to the study treatment
    • Time Frame: 12 months
    • To characterize the IgSCs safety, including the adverse events that are not considered to be related to the study treatment
  • Predictive Factors of Recurrent Infections
    • Time Frame: 12 months
    • To characterize potential predictive factors or markers of recurrent infections despite of the Ig treatment by collecting information about infections at follow up visits, especially bacterial infections and their respective antibiotherapy

Participating in This Clinical Trial

Inclusion Criteria

1. Adult male or female (≥18 years old), Myeloma or Chronic Lymphocytic Leukemia patients with secondary hypogammaglobinemia and recurring infections. 2. Patients with indication for IgSC treatment but who have not started the treatment yet. Prior IgSC or IgIV treatment 6 months before inclusion is accepted (with a washout period of 6 months minimum). 3. Patient having received all the necessary information about the study and signed an informed consent document. Exclusion Criteria:

1. Patient having initiated an IgSC treatment. 2. Patient having received IgSC or IgIV treatment within 6 months prior to inclusion. 3. Incapacity/Inability to attend the follow-up visits. 4. Patient refusing to participate in the study. 5. HIV positive patients. 6. Incapacity to understand the study objective and process, to agree or to give informed consent to participate in the study. 7. Pregnant or breast-feeding women

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Octapharma
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.